These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 2492455

  • 1. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 2. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 3. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May 01; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D.
    J Am Coll Cardiol; 1986 Jul 01; 8(1):118-24. PubMed ID: 3086416
    [Abstract] [Full Text] [Related]

  • 9. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1989 Apr 01; 39(4):534-8. PubMed ID: 2665759
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul 01; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 12. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF, Voytik S, Klabunde RE, Henkin J, Leski M.
    Thromb Res; 1988 Nov 15; 52(4):295-312. PubMed ID: 3144052
    [Abstract] [Full Text] [Related]

  • 13. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 15; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 14. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 15. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 24; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 16. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D, Van de Werf F.
    Am J Cardiol; 1987 Sep 01; 60(7):431-4. PubMed ID: 3115077
    [Abstract] [Full Text] [Related]

  • 17. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF.
    Circulation; 1990 Sep 01; 82(3):930-40. PubMed ID: 2118431
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 01; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.